Revvity unveils several next-generation preclinical imaging technologies to help scientists drive breakthrough discoveries

These new innovations include the next-generation IVIS® Spectrum 2 and the IVIS SpectrumCT 2 imaging systems

New Delhi: Revvity, Inc. debuts its enhanced imaging portfolio designed to drive innovation across diverse applications in preclinical research with the launch of three systems.
These new innovations include the next-generation IVIS® Spectrum 2 and the IVIS SpectrumCT 2 imaging systems, further elevating versatility and sensitivity standards in in vivo optical imaging. Also launching is the QuantumTM GX3 microCT structural imaging solution with increased resolution and speed for both in vivo and ex vivo imaging, designed to facilitate researchers studying disease biology or evaluating and fast-tracking therapeutic candidates. And making its global debut is the Vega® ultrasound system, originally launched in North America in 2022. These cutting-edge technologies will be showcased at the World Molecular Imaging Congress (WMIC) being held September 5-9, in Prague, Czech Republic.
  1. IVIS® Spectrum 2 and IVIS SpectrumCT 2imaging systems — new flagship platforms setting the standard in high-throughput performance and versatility
  2. QuantumTM GX3 microCT imaging solution — a high-throughput system with superior spatial resolution and fast, low-dose scanning for diverse in vivo and biological ex vivo applications
  3. Vega® preclinical ultrasound system — a hands-free, automated, high-throughput imaging system delivering high-resolution 2D and 3D ultrasound images in minutes, now globally available
According to Dr. Alan Fletcher, Senior Vice President of Life Sciences at Revvity, “In a time when innovative technologies steer medical advancements, we are committed to delivering 1 versatile, high-throughput solutions that enhance preclinical R&D productivity. Our growing portfolio equips researchers with robust capabilities to illuminate scientific discoveries and can expedite the journey from discovery to cure.”
Dr. Fletcher remarked, “Driven by ambitious product development and collaboration across the organization, our evolving portfolio underscores our commitment to accelerating innovation. With these advanced tools at their disposal, researchers can interrogate biology, streamline their workflows, and accelerate the pace of scientific advancement.”